Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Zacks.com on MSN17h
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
NVO’s success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. Wegovy is a ...
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
KOMU1d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
STAT1d
Vertex drug for cystic fibrosis wins approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
Yahoo Finance14d
Novo Banco ready to explore IPO opportunities, aims to stay independent
LISBON (Reuters) - Portugal's fourth-largest bank, Novo Banco, is ready to explore opportunities of going public to diversify its shareholder base as it hopes to remain an independent entity, the ...